Literature DB >> 15863610

Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.

Noah A Goldman1, Maria M de Los Angeles, Joan G Jones, Gary L Goldberg.   

Abstract

BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn.
CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863610     DOI: 10.1097/01.AOG.0000160480.55365.a8

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Authors:  Gloria S Huang; Rebecca C Arend; Maomi Li; Marc J Gunter; Lydia G Chiu; Susan Band Horwitz; Gary L Goldberg
Journal:  Am J Obstet Gynecol       Date:  2009-02-06       Impact factor: 8.661

2.  A case of extrauterine endometrial stromal sarcoma in the colon diagnosed three decades after hysterectomy for benign disease.

Authors:  Andres Ayuso; Oluwole Fadare; Dineo Khabele
Journal:  Case Rep Obstet Gynecol       Date:  2013-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.